← All reportsView on Symbol
MDGL

MDGL

High conviction

Madrigal Pharmaceuticals, Inc.

Healthcare · NASDAQ

$12.2B mkt cap

Brief updated Jul 6, 2026

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-t

Decifer Research·Data summary

MDGL is a high-conviction name in Healthcare

MDGL sits at the intersection of key themes currently active in the market. The scoring engine rates it high based on how well the active market forces line up with its business, plus available fundamental data. Financial metrics and analyst consensus provide additional context.

Why now

The market forces active right now are aligned with the company's core business exposure. The timing reflects the intersection of theme strength and available catalyst data.

Key risks

Data availability limits full scoring across all dimensions. Market forces can reverse rapidly; theme exposure does not guarantee the price follows. Fundamental valuation data may not reflect the most recent quarterly results.

What to watch

Monitor conviction score changes, especially the macro and analyst dimensions. Earnings guidance updates and analyst consensus shifts are the primary near-term catalysts.

56High conviction Conviction
macro
0/25
analyst
22/38
momentum
5/20
forward catalyst
4/15
valuation
23/23
highs
3/12
news catalyst
3/12
options flow
0/12
peer network
0/8
counter thesis
0/3
Key financials
Revenue growth (YoY)-304.0%
Gross margin9307.0%
Operating margin-2768.0%
Net margin-2732.0%
P/E ratio-49.5x
Return on equity-5015.0%
FCF yield-224.0%
Debt / equity0.6x
EV / sales10.9x
Valuation
Analyst consensusBUY
DCF fair value$2869
Next EPS estimate$-1.06
Macro context

Iran War Puts $124 Billion Gulf Remittance Lifeline at Risk

The Iran war poses a significant risk to the $124 billion Gulf remittance lifeline, which could have far-reaching consequences for the global economy and financial markets. This escalation of geopolitical tensions may lead to increased uncertainty and volatility in various asset classes.

Jun 22, 2026

Top Midday Stories: Treasury Authorizes Sale of Iranian Oil; SpaceX launches First Inaugural Bond Issuance

The US Treasury has authorized the sale of Iranian oil, potentially easing sanctions and allowing more oil to enter the global market, which could impact oil prices and the energy sector. This move may also have geopolitical implications, affecting relations between the US and Iran.

Jun 22, 2026

U.S. Military Expert Issues Grave Warning: ‘We Need More Munitions, and Deliveries Are Years Behind.’ What Stocks Can Benefit?

A U.S. military expert has warned that the country is facing a significant shortage of munitions, with deliveries years behind schedule, which could impact national security and defense capabilities. This warning highlights the need for increased production and procurement of munitions.

Jun 23, 2026

'Qatar Says US-Iran Hotline Essential To Reopen Strait of Hormuz' - FT

Qatar emphasizes the need for a US-Iran hotline to reopen the Strait of Hormuz, indicating heightened tensions in the region that could impact global oil supply and shipping routes. This development suggests an increased risk of conflict or disruption in a critical waterway.

Jun 24, 2026

Analyst intelligence
20 Buy2 Hold1 Sell
Earnings intelligence

Earnings surprises

+10.0%

2026-05

-6525.0%

2026-02

-149.4%

2025-11

+45.4%

2025-08

+8.3%

2025-05

Generated Mon, 06 Jul 2026 05:00:07 GMT by Decifer intelligence engine. For informational purposes only — not investment advice. Decifer Intelligence Hub.